A detailed history of Arizona State Retirement System transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Arizona State Retirement System holds 19,937 shares of CERE stock, worth $803,461. This represents 0.01% of its overall portfolio holdings.

Number of Shares
19,937
Previous 19,816 0.61%
Holding current value
$803,461
Previous $840,000 0.24%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$40.88 - $43.27 $4,946 - $5,235
121 Added 0.61%
19,937 $842,000
Q4 2023

Jan 24, 2024

BUY
$20.27 - $42.44 $39,607 - $82,927
1,954 Added 10.94%
19,816 $840,000
Q3 2023

Nov 06, 2023

BUY
$20.26 - $31.91 $5,287 - $8,328
261 Added 1.48%
17,862 $389,000
Q2 2023

Aug 01, 2023

SELL
$23.9 - $35.38 $12,356 - $18,291
-517 Reduced 2.85%
17,601 $559,000
Q1 2023

Apr 27, 2023

BUY
$22.82 - $35.32 $12,299 - $19,037
539 Added 3.07%
18,118 $441,000
Q4 2022

Feb 07, 2023

BUY
$25.35 - $31.96 $37,011 - $46,661
1,460 Added 9.06%
17,579 $554,000
Q3 2022

Nov 07, 2022

BUY
$25.5 - $41.42 $4,054 - $6,585
159 Added 1.0%
16,119 $456,000
Q2 2022

Jul 28, 2022

BUY
$20.62 - $37.15 $82,892 - $149,343
4,020 Added 33.67%
15,960 $422,000
Q1 2022

May 04, 2022

BUY
$23.5 - $35.38 $5,710 - $8,597
243 Added 2.08%
11,940 $418,000
Q4 2021

Feb 04, 2022

BUY
$29.21 - $44.64 $4,001 - $6,115
137 Added 1.19%
11,697 $379,000
Q3 2021

Nov 12, 2021

BUY
$21.26 - $38.85 $61,887 - $113,092
2,911 Added 33.66%
11,560 $341,000
Q2 2021

Aug 02, 2021

BUY
$12.56 - $29.69 $108,631 - $256,788
8,649 New
8,649 $222,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Market Cap $6.28B
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.